Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease

BACKGROUND: Epoetin beta pegol (continuous erythropoietin receptor activator; C.E.R.A.) is currently widely used for the treatment of anemia associated with chronic kidney disease (CKD). Therapeutic control of anemia is assessed by monitoring haemoglobin (Hb) levels. However, certain qualitative asp...

Descripción completa

Detalles Bibliográficos
Autores principales: Aizawa, Ken, Kawasaki, Ryohei, Tashiro, Yoshihito, Shimonaka, Yasushi, Hirata, Michinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787256/
https://www.ncbi.nlm.nih.gov/pubmed/29374477
http://dx.doi.org/10.1186/s12882-018-0818-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5787256/
https://www.ncbi.nlm.nih.gov/pubmed/29374477
http://dx.doi.org/10.1186/s12882-018-0818-4

Ejemplares similares